ТРЕТИЧНЫЙ ПОКАЗАТЕЛЬ ГЛИСОНА И СВЕРХМАЛЫЕ ЗНАЧЕНИЯ ПРОСТАТСПЕЦИФИЧЕСКОГО АНТИГЕНА КАК ФАКТОРЫ ПРОГНОЗА РЕЦИДИВА РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ
Аннотация
В литературе, посвященной изучению факторов прогноза биохимического рецидива, значительное место отводится обсуждению ультрачувствительных методов количественного определения сывороточного простатического специфического антигена (ПСА). Несколько исследований показали, что главной ценностью сверхмалых значений ПСА могут быть выделение пациентов группы высокого риска прогрессирования и, как следствие, раннее выявление рецидива заболевания. Кроме этого, предметом специального изучения является присутствие и определение третичного показателя Глисона в образцах опухоли предстательной железы, полученных после радикальной простатэктомии. В литературе появляется все больше данных о том, что третичный показатель связан с неблагоприятными патоморфологическими характеристиками и более высоким риском биохимического рецидива.
Список литературы
1. Воробьев А.В. Рак предстательной железы: эволюция взглядов. Вопр онкол 2009;55(2):241–9.
2. Han M., Partin A.W., Chan D.Y. et al. An evaluation of the decreasing incidence of positive surgical margins in a large retropubic prostatectomy series. J Urol 2004;171:23–6.
3. Ahyai S.A., Zacharias M., IsbarnH. et al. Prognostic significance of a positive surgical margin in pathologically organ-confined prostate cancer. BJU International 2010;106(4):478–83.
4. Graefen M., Walz J., Huland H. Open retropubic nerve-sparing radical prostatectomy. Eur Urol 2006;49:38–48.
5. Велиев Е.И. Оптимизация хирургического лечения больных локализованным раком предстательной железы. Дис. … д-ра мед. наук. СПб., 2003. 348 с.
6. Zincke H., Oesterling J.E., Blute M.L. et al. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994;152(5 Pt 2):1850–7.
7. Liu L., Coker A.L., Du X.L. et al. Long-term survival after radical prostatectomy compared to othertreatments in older men with local/regional prostate cancer. J Surg Oncol 2008;97:583–91.
8. Krongrad A., Lai H., Lai S. Survival after radical prostatectomy. JAMA 1997;278(1):44–6.
9. Kupelian P.A., Katcher J., Levin H.S. et al. Stage T1-2 prostate cancer a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Int J Radiat Oncol Biol Phys 1997;37:1043–52.
10. Catalona W.J., Smith D.S. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 1994;152:1837–42.
11. Walsh P.C., Partin A.W., Epstein J.I. Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol 1994;152 (5):1831–6.
12. Frazier H.A., Robertson J.E., Humphrey P.A. et al. Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy. J Urol 1993;149(3):516–8.
13. Hull G.W., Rabbani F., Abbas F. et al. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002;167(2 Pt 1):528–34.
14. Grossfeld G.D., Chang J.J., Broering J.M. et al. Does the completeness of prostate sampling predict outcome for patients undergoing radical prostatectomy: data from the CAPSURE database. Urology 2000;56(3):430–5.
15. Han M., Partin A.W., Zahurak M. et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003;169(2):517–23.
16. Amling C.L., Blute M.L., Bergstralh E.J. et al. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol 2000;164(2):101–5.
17. Roehl K.A., Han M., Ramos C.G. et al. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 2004;172(3):910–4.
18. Porter C.R., Gallina A., Kodama K. et al. Prostate cancer-specific survival in men treated with hormonal therapy after failure of radical prostatectomy. Eur Urol 2007;52 (2):446–52.
19. Oefelein M.G., Smith N., Carter M. et al. The incidence of prostate cancer progression with undetectable serum prostate specific antigen in a series of 394 radical prostatectomies. J Urol 1995;154(6):2128–31.
20. Vessella R.L. Trends in immunoassays of prostate-specific antigen: serum complexes and ultrasensitivity. Clin Chem1993;39(10):2035–9.
21. Stamey T.A., Graves H.C., Wehner N. et al. Early detection of residual prostate cancer after radical prostatectomy by an ultrasensitive assay for prostate specific antigen. J Urol 1993;149(4):787–92.
22. Ferguson R.A., Yu H., Kalyvas M. et al.Ultrasensitive detection of prostate-specific antigen by a time-resolved immunofluorometric assay and the Immuliteimmunochemiluminescent third-generation assay: potential applications in prostate and breast cancers. Clin Chem 1996;42(5):675–84.
23. Ellis W.J., Vessella R.L., Noteboom J.L. et al. Early detection of recurrent prostate cancer with an ultrasensitive hemiluminescent prostate- specific antigen assay. Urology 1997;50(4):573–9.
24. Doherty A.P., Bower M., Smitрhetal G.L. Undetectable ultrasensitive PSA after radical prostatectomy for prostate cancer predicts relapse-free survival. Br J Cancer 2000;83(11):1432–6.
25. SakaiI., Harada K., Kurahashi T. et al. Usefulness of the nadir value of serum prostate-specific antigen measured by an ultrasensitive assay as a predictor of biochemical recurrence after radical prostatectomy for clinically localized Prostate Cancer. UrolInt 2006;76(3):227–31.
26. Shen S., Lepor H., Yaffee R. et al. Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy. J Urol 2005;173:777–80.
27. Vesely S., Jarolim L., Babjuk M. et al. Ultrasensitive prostate-specific antigen nadir and time to nadir as independent predictors of biochemical recurrence in patients after radical prostatectomy for localized prostate cancer. Eur Urol Suppl 2010;10 (2):274.
28. Malik R.D., Goldberg J.D., Hochman T. et al. Three-year postoperative ultrasensitive prostate-specific antigen following open radical retropubic prostatectomy is a predictor for delayed biochemical recurrence. Eur Urol 2011;60(3):19–28.
29. Pan C.C., Potter S.R., Partin A.W. et al. The prognostic significance of tertiary Gleason patterns of higher grade in radical prostatectomy specimens: a proposal to modify the Gleason grading system. Am J Surg Pathol 2000;24:563–9.
30. Epstein J.I., Allsbrook W.C., Amin M.B. et al. ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 2005;29:1228–42.
31. Egevad L., Granfors T., Karlberg L. et al. Percent Gleason grade 4/5 as prognostic factor in prostate cancer diagnosed at trans-urethral resection. J Urol 2002;168:509–13.
32. Rasiah K.K., Stricker P.D., Haynes A.M. et al. Prognostic significance of Gleason pattern in patients with Gleason score 7 prostate carcinoma. Cancer 2003;98:2560–5.
33. Mosse C.A., Magi-Galluzzi C., Tsuzuki T. The prognostic significance of tertiary Gleason pattern 5 in radical prostatectomy specimens. Am J Surg Pathol 2004;28:394–8.
34. Hattab E.M., Koch M.O., Eble J.N. et al. Tertiary Gleason pattern 5 is a powerful predictor of biochemical relapse in patients with Gleason score 7 prostatic adenocarcinoma. J Urol 2006;175:1695–9.
35. Harnden P., Shelley M.D., Coles B. et al. Should the Gleason grading system for prostate cancer be modified to account for high-grade tertiary components? A systematic review and meta-analysis. Lancet Oncol 2007;8:411–9.
36. Sim H.G., Telesca D., Culp S.H. et al. Tertiary Gleason pattern 5 in Gleason 7 prostate cancer predicts pathological stage and biochemical recurrence. J Urol 2008;179:1775–9.
37. Whittemore D.E., Hick E.J., Carter M.R. et al. Significance of tertiary Gleason pattern 5 in Gleason score 7 radical prostatectomy specimens. J Urol 2008;179:516–22.
38. Ruijter E.T., van de Kaa C.A., Schalken J.A. et al. Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications. J Pathol 1996;180:295–9.
39. Harnden P., Shelley M.D., Coles B. et al. Should the Gleason grading system for prostate cancer be modified to account for high-grade tertiary components? A systematic review and meta-analysis. Lancet Oncol 2007;8(5):411–9.
40. Patel A.A., Chen M.H., Renshaw A.A. et al. PSA failure following definitive treatment of prostate cancer having biopsy Gleason score 7 with tertiary grade 5. JAMA 2007;298(13):1533–8.
41. Turker P., Bas E., Bozkurt S. et al. Presence of high grade tertiary Gleason pattern upgrades the Gleason sum score and is inversely associated with biochemical recurrence-free survival. Urol Oncol 2011 [Epub ahead of print].
42. Hashine K., Yuasa A., Shinomori K. et al. Tertiary Gleason pattern 5 and oncological outcomes after radical prostatectomy. Jpn J Clin Oncol 2011;41 (4):571–6.
43. Isbarn H., Ahyai S.A., Chun F.K. et al. Prevalence of a tertiary Gleason grade and its impact on adverse histopathologic parameters in a contemporary radical prostatectomy series. Eur Urol 2009;55(2):394–401.
44. Oort I.M., Schout B.M., Kiemeney L.A. L.M. et al. Does the tertiary Gleason pattern influence the PSA progression-free interval after retropubic radical prostatectomy for organ-confined prostate cancer? Eur Urology 2005;48(4):572–6.
Для цитирования:
Огнерубова И.Н. ТРЕТИЧНЫЙ ПОКАЗАТЕЛЬ ГЛИСОНА И СВЕРХМАЛЫЕ ЗНАЧЕНИЯ ПРОСТАТСПЕЦИФИЧЕСКОГО АНТИГЕНА КАК ФАКТОРЫ ПРОГНОЗА РЕЦИДИВА РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ. Онкоурология. 2013;9(1):50-54. https://doi.org/10.17650/1726-9776-2013-9-1-50-54
For citation:
Ognerubova I.N. TERTIARY GLEASON GRADE ANDULTRASENSITIVE PROSTATE-SPECIFIC ANTIGEN LEVELS AS PROGNOSTIC FACTOR OF PROSTATE CANCER RECURRENCE. Cancer Urology. 2013;9(1):50-54. (In Russ.) https://doi.org/10.17650/1726-9776-2013-9-1-50-54
Просмотров: 510
Послать статью по эл. почте 
